Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

5037 - Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database


11 Sep 2017


Immunotherapy of cancer


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy


Gaurav Singal


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


G. Singal1, P.G. Miller2, V. Agarwala3, G. Li4, A. Gossai5, L.A. Albacker6, M.E. Goldberg6, J. He4, S. Frank5, D. Bourque7, I. Ivanov5, D. Fabrizio8, T. Caron5, A. Parker7, A. Guria4, V.A. Miller9, J.A. Elvin10, J.S. Ross10, A. Abernethy11, P.J. Stephens6

Author affiliations

  • 1 Data Strategy, Foundation Medicine, 02141 - Cambridge/US
  • 2 Oncology, Dana Farber Cancer Institute, Boston/US
  • 3 Product, Flatiron Health, Inc., New York/US
  • 4 Data Science, Foundation Medicine, Cambridge/US
  • 5 Data Science, Flatiron Health, Inc., New York/US
  • 6 R&d, Foundation Medicine, Cambridge/US
  • 7 Data Strategy, Foundation Medicine, Cambridge/US
  • 8 Cancer Immunotherapy, Foundation Medicine, Cambridge/US
  • 9 Medical Group, Foundation Medicine, Cambridge/US
  • 10 Pathology, Foundation Medicine, Cambridge/US
  • 11 Medical Group, Flatiron Health, Inc., New York/US


Abstract 5037


Highly discriminating biomarkers of response to cancer immunotherapies (CIT) remain elusive. Characterization of large real-world populations treated with CIT as part of routine care may enable better stratification.


Patients in the Flatiron Health Analytic Database with non-small cell lung cancer (NSCLC) who underwent comprehensive genomic profiling (CGP) by Foundation Medicine were included (n = 2139). CGP included >300 genes and tumor mutation burden (TMB), stratified into low (TMB-L;  =20 mut/MB) tertiles (Johnson, CIR 2016). PD-L1 expression was obtained from results reported to clinicians from multiple labs (using varying antibodies). Genomic data was linked to de-identified electronic health record (EHR) data, from which nivolumab response was measured as overall response rate (ORR = SD, PR, or CR), median duration of therapy (mDOT), and median overall survival (mOS) from advanced diagnosis and from nivolumab initiation.


In patients treated with nivolumab (n = 444, 20.8%), TMB-H predicted longer mDOT than TMB-L/I (7.5 vs 4.6 months, p = 0.001), mOS from start of nivolumab treatment (median not reached vs 10 months, p 


Real-world datasets combining clinical outcomes with genomic profiling may enable biomarker discovery in CIT. These data demonstrate the predictive power of TMB, which can augment and significantly improve on the currently approved PD-L1 expression as a predictor of CIT response. They may also enable discovery of novel biomarkers that can identify potential CIT responders among TMB-L populations.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine, Inc. and Flatiron Health, Inc.




G. Singal: Employee of Foundation Medicine, Inc., with equity and salary. P.G. Miller: Consultant with Foundation Medicine, Inc. V. Agarwala: Employee and shareholder of Flatiron Health, Inc. G. Li, L.A. Albacker, M.E. Goldberg, J. He, D. Bourque, D. Fabrizio, A. Parker, A. Guria, V.A. Miller, J.A. Elvin, J.S. Ross, P.J. Stephens: Employee and shareholder of Foundation Medicine, Inc. A. Gossai, S. Frank, I. Ivanov, T. Caron, A. Abernethy: Employee and shareholder of Flatiron Health, Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.